Virpax Pharmaceuticals, Inc. – NASDAQ:VRPX
Virpax Pharmaceuticals stock price today
$0.011
-0.39
-97.32%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 2 hours
Virpax Pharmaceuticals stock price monthly change
-69.85%
month
Virpax Pharmaceuticals stock price quarterly change
-69.85%
quarter
Virpax Pharmaceuticals stock price yearly change
+20.94%
year
Virpax Pharmaceuticals key metrics
Market Cap | 2.72M |
Enterprise value | N/A |
P/E | -0.4 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.52 |
PEG ratio | -0.01 |
EPS | -14.42 |
Revenue | N/A |
EBITDA | -17.34M |
Income | -16.88M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeVirpax Pharmaceuticals stock price history
Virpax Pharmaceuticals stock forecast
Virpax Pharmaceuticals financial statements
| Jun 2023 | 0 | -3.11M | |
|---|---|---|---|
| Sep 2023 | 0 | -5.99M | |
| Dec 2023 | 0 | -4.56M | |
| Mar 2024 | 0 | -3.22M |
| 2025 | 0 | -15.71M | |
|---|---|---|---|
| 2026 | 0 | -17.59M | |
| 2027 | 56.59M | 1.42M | 2.52% |
| 2028 | 97.38M | 4.42M | 4.55% |
Analysts Price target
Financials & Ratios estimates
| 2023-11-15 | -0.26 | -0.51 |
|---|---|---|
| 2024-03-26 | -2.7 | -3.9 |
| Jun 2023 | 15951368 | 3.64M | 22.86% |
|---|---|---|---|
| Sep 2023 | 13038387 | 6.53M | 50.1% |
| Dec 2023 | 9628345 | 7.69M | 79.91% |
| Mar 2024 | 3130407 | 4.34M | 138.76% |
| Jun 2023 | -2.18M | 0 | 0 |
|---|---|---|---|
| Sep 2023 | -2.65M | 0 | 0 |
| Dec 2023 | -3.01M | 0 | 0 |
| Mar 2024 | -7.72M | 0 | 453.95K |
Virpax Pharmaceuticals alternative data
| Aug 2023 | 7 |
|---|---|
| Sep 2023 | 7 |
| Oct 2023 | 7 |
| Nov 2023 | 7 |
| Dec 2023 | 7 |
| Jan 2024 | 7 |
| Feb 2024 | 7 |
| Mar 2024 | 7 |
| Apr 2024 | 7 |
| May 2024 | 7 |
| Jun 2024 | 7 |
| Jul 2024 | 7 |
Virpax Pharmaceuticals other data
1.09%
-12.16%
of VRPX is owned by hedge funds
127.95K
-1.42M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2021 | 29025 | 0 |
| May 2022 | 84729 | 0 |
| Insider | Compensation |
|---|---|
Mr. Anthony P. Mack M.B.A. (1962) Chairman & Chief Executive Officer | $375,000 |
Mr. Christopher M. Chipman CPA, CPA (1972) Chief Financial Officer & Corporation Sec. | $72,000 |
-
What's the price of Virpax Pharmaceuticals stock today?
One share of Virpax Pharmaceuticals stock can currently be purchased for approximately $0.01.
-
When is Virpax Pharmaceuticals's next earnings date?
Unfortunately, Virpax Pharmaceuticals's (VRPX) next earnings date is currently unknown.
-
Does Virpax Pharmaceuticals pay dividends?
No, Virpax Pharmaceuticals does not pay dividends.
-
How much money does Virpax Pharmaceuticals make?
Virpax Pharmaceuticals has a market capitalization of 2.72M. Virpax Pharmaceuticals made a loss 15.19M US dollars in net income (profit) last year or -$3.9 on an earnings per share basis.
-
What is Virpax Pharmaceuticals's stock symbol?
Virpax Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "VRPX".
-
What is Virpax Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Virpax Pharmaceuticals?
Shares of Virpax Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Virpax Pharmaceuticals's key executives?
Virpax Pharmaceuticals's management team includes the following people:
- Mr. Anthony P. Mack M.B.A. Chairman & Chief Executive Officer(age: 63, pay: $375,000)
- Mr. Christopher M. Chipman CPA, CPA Chief Financial Officer & Corporation Sec.(age: 53, pay: $72,000)
-
How many employees does Virpax Pharmaceuticals have?
As Jul 2024, Virpax Pharmaceuticals employs 7 workers.
-
When Virpax Pharmaceuticals went public?
Virpax Pharmaceuticals, Inc. is publicly traded company for more then 4 years since IPO on 17 Feb 2021.
-
What is Virpax Pharmaceuticals's official website?
The official website for Virpax Pharmaceuticals is virpaxpharma.com.
-
Where are Virpax Pharmaceuticals's headquarters?
Virpax Pharmaceuticals is headquartered at 1055 Westlakes Drive, Berwyn, PA.
-
How can i contact Virpax Pharmaceuticals?
Virpax Pharmaceuticals's mailing address is 1055 Westlakes Drive, Berwyn, PA and company can be reached via phone at +61 7274597.
Virpax Pharmaceuticals company profile:
Virpax Pharmaceuticals, Inc.
virpaxpharma.comExchange:
NASDAQ
Full time employees:
7
Industry:
Biotechnology
Sector:
Healthcare
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
1055 Westlakes Drive
Berwyn, PA 19312
Berwyn, PA 19312
CIK: 0001708331
ISIN: US9282512063
CUSIP: 928251206
